NFKB1 and metabolic dysfunction-associated steatotic liver disease: Thus, future investigations are required to determine whether NTP can be a new therapeutic agent for chronic liver disease, in particular, alcoholic and non-alcoholic fatty liver disease, in which NF-κB and JNK are thought to take part.